Table 3.
Grade 3 or higher adverse events and discontinuation due to adverse events
| LFP | Sorafenib | |
|---|---|---|
| Neutrophil count decreased | 4 | |
| Platelet count decreased | 8 | 1 |
| Aspartate aminotransferase increased | 1 (3) | 2 |
| Alanine aminotransferase increased | 1 (3) | 1 |
| Creatinine increased | 1 | |
| Amylase increased | 1 | |
| Hypophosphatemia | 2 | |
| Hyponatremia | 2 | |
| Diarrhea | 1 | |
| Hepatic encephalopathy | 1 | 1 |
| General malaise | 3 | |
| Appetite loss | 2 | |
| Erythema exsudativum multiforme | 1 | |
| Hepatic artery occlusion | 1 | |
| Cerebellar infarction | 1 | |
| Discontinuation due to adverse events | 3 | 7 |
The numerical data represent the number of cases. Figures in parentheses represent the number of cases showing a transient increase after the placement of a reservoir catheter. There was a significant difference in the rate of discontinuation due to adverse events between the LFP group and the sorafenib group. LFP, low-dose 5-fluorouracil and cisplatin.